Jessica M. Haddad

Jessica M. Haddad

Auto-generated profile, based on publicly available information

Jessica M. Haddad

Harvard Medical School and Brigham and Women’s Hospital

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2021 in Current Psychiatry Reports
Verified
Journal Article
Closed access
PDF file
JHJessica M. Haddad
Jessica M. Haddad
CMChristina Macenski
Christina Macenski
AMAlison Mosier-Mills
Alison Mosier-Mills
AHAlice Hibara
Alice Hibara
KKKatherine Kester
Katherine Kester
CLCindy H. Liu
Cindy H. Liu

27 April 2021 in Journal of Genetic Counseling
Verified
Journal Article
Closed access
PDF file
JHJessica M. Haddad
Jessica M. Haddad
KRKatina Robison
Katina Robison
LBLindsey Beffa
Lindsey Beffa
JLJessica Laprise
Jessica Laprise
JSJennifer ScaliaWilbur
Jennifer ScaliaWilbur
ASAshley Stuckey
Ashley Stuckey

20 July 2023 in Current Psychiatry Reports
Verified
Journal Article
Closed access
PDF file
JAJames Aluri
James Aluri
JHJessi M. Haddad
Jessi M. Haddad
SPSusan Parke
Susan Parke
VSVictor Schwartz
Victor Schwartz
SJShashank V Joshi
Shashank V Joshi
RCRachel C. Conrad
Rachel C. Conrad

20 May 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SAS. S. Agarwala
S. S. Agarwala
JHJ. Haddad
J. Haddad
EJE. Jacobson
E. Jacobson
14595 Background: Elesclomol is a novel small-molecule oxidative stress inducer known to synergize with taxanes and certain other chemotherapeutics. Co-administered with paclitaxel (E+P), it demonstrated encouraging activity in metastatic melanoma in a recent Phase 2 trial. Methods: Between 2003 and 2006 at >20 sites, a total of 3 Phase 1 (solid tumors) and 2 Phase 2 (melanoma, sarcoma) clinical trials of E+P were completed. Various dose regimens were explored, and 1 randomized, blinded study had a paclitaxel control. Exposure, adverse event (AE) and lab data were combined. All AE data were graded per CTCAE v.3 and re-coded to MedDRA 9.0. All treated patients (pts) were analyzed by treatment received. Results: 239 pts received E+P, with 224 receiving E at or above 213 mg/m2, the dose currently under investigation in a Phase 3 trial in metastatic melanoma. Of 269 total treated pts, 62% were male, 89% were Caucasian; mean age = 57. Mean E+P treatment duration = 85 d (range 1 to 554 d). The most frequent AEs for E+P pts were fatigue, alopecia, nausea, constipation, and diarrhea. The most frequent ≥ Grade 3 AEs are presented below; P-alone blinded control data (metastatic melanoma) are given for comparison. Lab data show a small incidence increase in ≥ Grade 3 neutropenia for the E+P group vs. P alone. The most frequent non-neoplastic AEs resulting in E+P discontinuation were hypersensitivity reactions, neuropathic events, and respiratory disorders; comparable %s of P-alone pts discontinued P for these reasons. Conclusions: Given via various dosing regimens to oncology populations, E+P demonstrated small toxicity increases over P alone and was generally well tolerated. Observed E+P toxicities were typical of taxane administration. No ≥ Grade 3 AE exceeded 10%. Slight incidence increases for ≥ Grade 3 neutropenia were observed; a small P-alone sample limits interpretation.

12 October 2022 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
ETEdward Thomas
Edward Thomas
JHJessica M. Haddad
Jessica M. Haddad

1 February 2021 in Psychiatric Annals
Verified
Journal Article
Closed access
PDF file
JHJessica Haddad
Jessica Haddad
KCKyle Curtis
Kyle Curtis
CKCarmen Kilpatrick
Carmen Kilpatrick
ACAlison Chambers
Alison Chambers
PHPamela Hoffman
Pamela Hoffman
KDKathleen Donise
Kathleen Donise